Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: Deep hyperthermia combined with platinum-based chemotherapy (DHCT) might lead to the development of better therapeutic strategy for patients with malignant tumor. This study aimed to analyze the computational medical differences in ovarian cancer patients treated with DHCT compared with platinum-based chemotherapy alone.
Methods: 78 patients with advanced ovarian cancer admitted from November 2017 to November 2021 were randomly selected as subjects. Overall survival analysis and CA125 clinical efficiency evaluation were performed to explore the effect of DHCT on cis-platinum therapy. All patients were informed and consented, and approved by the hospital committee. The data were systematically analyzed by chi-squared test to analyze clinical effect and safety observation, and the Kaplan-Meier method and log-rank test were used for survival analysis.
Results: Survival analysis showed that DHCT was strongly associated with improved overall survival (OS) in the platinum treatment of ovarian cancer patients (Hazard Ratio = 1.57, 95% CI: 0.93-2.44, P = .017). For ovarian cancer patients receiving lobaplatin treatment, DHCT could also elevate their survival (Hazard Ratio = 1.52, 95% CI :1.02-2.25, P = .013). The study also showed a statistically significant difference in clinical outcomes between the two groups (P < .001), and the opposite is true for adverse reactions.
Conclusion: Our results suggest that DHCT is expected to be combined with platinum chemotherapy, which is helpful for the molecular classification of ovarian cancer patients. More studies are needed to further verified the clinical significance.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Estrogen therapy in patients with gynecologic cancer: a survey of gynecologists and oncologists in the United States.
Menopause
September 2025
Department of Gynecologic Oncology, Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY.
Objective: Endometrial cancer (EC) and epithelial ovarian cancer (EOC) affect women of all ages, and the incidence of endometrial cancer in premenopausal women is rising. Menopause can be detrimental to longevity and quality of life, but evidence suggests estrogen therapy (ET) is safe in these patients. The purpose of this study was to evaluate the practice patterns of gynecologists and gynecologic oncologists (GYO) in the United States in regards to prescription of ET to gynecologic cancer patients.
View Article and Find Full Text PDFSTmiR: A Novel XGBoost-based framework for spatially resolved miRNA activity prediction in cancer transcriptomics.
PLoS One
September 2025
Institute of Computational Science and Technology, Guangzhou University, Guangzhou, China.
MicroRNAs (miRNAs) are critical regulators of gene expression in cancer biology, yet their spatial dynamics within tumor microenvironments (TMEs) remain underexplored due to technical limitations in current spatial transcriptomics (ST) technologies. To address this gap, we present STmiR, a novel XGBoost-based framework for spatially resolved miRNA activity prediction. STmiR integrates bulk RNA-seq data (TCGA and CCLE) with spatial transcriptomics profiles to model nonlinear miRNA-mRNA interactions, achieving high predictive accuracy (Spearman's ρ > 0.
View Article and Find Full Text PDFManagement of ocular toxicity in patients with gynecologic cancer receiving novel antibody-drug conjugates: a narrative review.
Clin Transl Oncol
September 2025
Ophthalmology Unit, Cannizzaro Hospital, 95126, Catania, Italy.
Antibody-drug conjugates (ADCs) represent a promising therapeutic approach in gynecologic cancers, particularly ovarian and cervical malignancies. Agents such as mirvetuximab soravtansine, and tisotumab vedotin, targeting folate receptor alpha and tissue factor, respectively, reported clinical efficacy in patients with limited options. However, their use is associated with ocular toxicities, including keratopathy, blurred vision, and dry eye, which may impact adherence and quality of life.
View Article and Find Full Text PDFUTND Effect Mediates Macrophage Ferroptosis and Promotes Immune Microenvironment Remodeling of Ovarian Cancer.
FASEB J
September 2025
Department of Obstetrics, Obstetrics and Gynecology Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Tumor-associated macrophages (TAMs) act as a vital player in the immunosuppressive tumor microenvironment (TME) and have received widespread attention in the treatment of cancer in recent times. Nevertheless, simultaneously inducing TAM repolarization and strengthening their phagocytic ability on cancer cells is still a significant challenge. Ferroptosis has received widespread attention due to its lethal effects on tumor cells, but its role in TAMs and its impact on tumor progression have not yet been defined.
View Article and Find Full Text PDFTargeting LxCxE cleft pocket of retinoblastoma protein in immunosuppressive macrophages inhibits ovarian cancer progression.
Cancer Immunol Res
September 2025
The Wistar Institute, Philadelphia, PA, United States.
Ovarian cancer remains a major health threat with limited treatment options available. It is characterized by immunosuppressive tumor microenvironment (TME) maintained by tumor-associated macrophages (TAMs) hindering anti-tumor responses and immunotherapy efficacy. Here we show that targeting retinoblastoma protein (Rb) by disruption of its LxCxE cleft pocket causes preferential cell death in Rbhigh M2 polarized or M2-like Rbhigh immunosuppressive TAMs by induction of ER stress, p53 and mitochondria-related cell death pathways.
View Article and Find Full Text PDF